Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor with cytarabine and idarubicin for relapsed or refractory acute myeloid leukemia
2014-000526-37Phase 2Completed
- Sponsor
- GSO Global Clinical Research
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor in acute myeloid leukemia (AML), sponsored by GSO Global Clinical Research. Primary endpoint: Complete remission or CRi rate. Started Jun 2014; status: completed.
02
Drugs
selinexor
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2014-000526-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000526-37.